Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen, or vindesine plus tamoxifen: A prospective randomized study

Melanoma Research

Volumn 13, Issue 1, 2003, Pages 73-79

  Cocconi, G ^a,c   Passalacqua, R ^a   Foladore, S ^a   Carlini, P ^a   Acito, L ^a   Maiello, E ^a   Marchi, M ^a   Gebbia, V ^a   Di Sarra, S ^a   Beretta, M ^a   Bacchi, M ^a,b  

^a Ital Oncol Grp Clin Res GOIRC   (Italy)

^b Serono International   (Switzerland)

^c Serono International ^*  (Italy)

Author keywords

Dacarbazine; Metastatic malignant melanoma; Randomized clinical trial; Tamoxifen; Vindesine

Indexed keywords

DACARBAZINE; TAMOXIFEN; VINDESINE;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIARRHEA; DRUG EFFECT; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MELANOMA; NAUSEA; PERIPHERAL NEUROPATHY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DACARBAZINE; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; SKIN NEOPLASMS; SURVIVAL RATE; TAMOXIFEN; TREATMENT OUTCOME; VINDESINE;

EID: 0037331681     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-200302000-00012     Document Type: Article

References (18)

1. Cocconi G, Bella M, Calabresi F, Tonato M, Canaletti R, Boni C, et al. Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. N Engl J Med 1992; 327:516-523.
2. Wittes RE, Adrianza ME, Parsons R, Feliz J, Marsoni S. Compilation of phase II results with single antineoplastic agents. Cancer Treat Symposia 1985; 4:1-477.
3. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadd ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5:649-655.
4. Miller AR, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47:207-214.
5. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-481.
6. Peto P, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Br J Cancer 1977; 35:1-39.
7. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50:163-170.
8. Balck CM, Reingen DS, Kirkwood JM, Houghton A, Peters L, Kian Ang K. Cutaneous melanoma. In: De Vita VT Jr, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology, 5th edition. Philadelphia: Lippincott; 1997, pp. 1947-1994.
9. Guerry DP, Schuchter LM. Disseminated melanoma. Is there a new standard therapy? N Engl J Med 1992; 327:560-561.
10. Chiarion Sileni V, Nortilli R, Aversa SML, Paccagnella A, Medici M, Corti L, et al. Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients. Melanoma Res 2001; 11:189-196.
11. Buzaid AC, Legha S, Winn R, Belt R, Pollock T, Wiseman C, et al. Cisplatin (C), vinblastine (V), and dacarbazine (D) (CVD) versus dacarbazine alone in metastatic melanoma: preliminary results of a phase III cancer community oncology program (CCOP) trial. Proc Am Soc Clin Oncol 1993; 12:389.
12. Sertoli MR, Queirolo P, Bajetta E, DelVecchio M, Comella G, Barduagni L, et al. Multi-institutional phase II trial of integrated therapy with cisplatin, dacarbazine, vindesine, subcutaneous interleukin-2, interferon alpha2a and tamoxifen in metastatic melanoma. BREMIM (Biological Response Modifiers in Melanoma). Melanoma Res 1999; 9:503-509.
13. Flaherty LE, Liu PY, Unger J, Sondak VK. Comparison of patient characteristics and outcome between a single-institution phase II trial and a cooperative-group phase II trial with identical eligibility in metastatic melanoma. Am J Clin Oncol 1997; 20:600-604.
14. Maibach R, Laffer U, Metzer U, Hess P, Waltzer U, Castiglione M. Contradictory results from consecutive trials: a cautious approach to explanations. Control Clin Trials 1997; 18:123.
15. Balch CM, Soong S-j, Shaw HM, Urist MM, McCarthy WH. An analysis of prognostic factors in 8500 patients with cutaneous melanoma. In Balch CM, Houghton AN, Milton GW, Sober AJ, Soong S-j, editors. Cutaneous melanoma, 2nd edition. Philadelphia: Lippincott; 1991. pp. 165-187.
16. Barth A, Wanek LA, Morton DL. Prognostic factors in 1521 melanoma patients with distant metastases. J Am Coll Surg 1995; 181:193-291.
17. Unger JM, Flaherty LE, Liu PY, Albain KS, Sondak VK. Gender and other survival predictors in patients with metastatic melanoma on Southwest Oncology Group trials. Cancer 2001; 91:1148-1155.
18. Lee M, Tomsu K, Von Eschen KB. Duration of survival for disseminated malignant melanoma: results of a meta-analysis. Melanoma Res 2000; 10:81-92.